File(s) not publicly available
Characteristics of Australian smokers using bupropion and nicotine-replacement therapies
journal contribution
posted on 2018-08-06, 00:00 authored by Christopher DoranChristopher Doran, J Stafford, M Shanahan, RP MattickSmokers were surveyed using a computer-assisted telephone interview to explore behaviors associated with the use of buproplon and nicotine-replacement therapies, using a convenient sample of Australian smokers. With assistance from the Pharmacy Guild of Australia, smokers were recruited through pharmacies and interviewed at baseline and after 3 months. A total of 508 smokers were recruited, 396 were interviewed at baseline and 318 completed a 3-month computer-assisted telephone interview. At 3 months, over two-thirds of participants were still smoking, the majority daily. However, the number of cigarettes smoked per week reduced and the time taken before smoking the first cigarette after waking increased. Nearly all participants started their medication (94%), while only 39% completed the full course. The main reasons for not completing the full course were adverse side effects, such as abnormal dreams and sleep disturbance. Despite Australian guidelines for bupropion and nicotine-replacement therapies to be used within a comprehensive treatment program, only 11% of patients were recommended behavioral support for nicotine dependence by their doctor or pharmacist. The results of the study shed light on patient utilization of the medication in terms of uptake and completion, possible side effects experienced and use of adjuncts. A better understanding of the use and experience of bupropion and nicotine-replacement therapies, and the lack of behavioral support offered with these, provides policy makers with a stronger evidence base to refine and improve the use of such pharmacotherapies. © 2007 Future Drugs Ltd.
Funding
Other
History
Volume
7Issue
1Start Page
41End Page
47Number of Pages
7eISSN
1744-8379ISSN
1473-7167Publisher DOI
Peer Reviewed
- Yes
Open Access
- No
Era Eligible
- Yes
Journal
Expert Review of Pharmacoeconomics and Outcomes ResearchUsage metrics
Categories
Licence
Exports
RefWorksRefWorks
BibTeXBibTeX
Ref. managerRef. manager
EndnoteEndnote
DataCiteDataCite
NLMNLM
DCDC